In a phase 3 trial involving infants in China, ziresovir, an orally administered RSV F protein inhibitor, led to an improvement in the Wang bronchiolitis score at day 3 and a decline in the RSV viral load by day 5.
The New England Journal of Medicine: Search Results in Pediatrics
